Substituted tetracycline compounds
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
1. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
3. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
4. A compound selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 2 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 3 and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 4 and a pharmaceutically acceptable carrier.
9. The compound of claim 2 , wherein said compound is:
10. The compound of claim 3 , wherein said compound is:
11. The compound of claim 4 , wherein said compound is:
12. The pharmaceutical composition of claim 6 , wherein said compound is:
13. The pharmaceutical composition of claim 7 , wherein said compound is:
14. The pharmaceutical composition of claim 8 , wherein said compound is: